Premarket Decliner
NSRX Nasus Pharma Ltd.5.00+0.38+8.2%
Premarket:4.00-1.00 (-20.0%)
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold
Globe NewswireMon, 16-Mar 7:30 AM
